Targets › CXCR1
4 programs from 4 companies in 18 trials: 11 Phase 1, 6 Phase 2, 1 Phase 3; Oncology, Hematology, Immunology; next expected readout Jan 2027.
Receptor to interleukin-8, which is a powerful neutrophils chemotactic factor. Binding of IL-8 to the receptor causes activation of neutrophils. (UniProt, P25024)
Open in Phaseline: the race on CXCR1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | BIO 300 Interleukin-8 receptors, CXCR1/CXCR2 inhibitor | CXCR2, CXCR1 | Phase 3 | Multiple Myeloma; NSCLC; Diarrhea; Cutaneous Squamous Cell Carcinoma … | Jan 2027 |
| Syntrix Biosystems | SX-682 Interleukin-8 receptors, CXCR1/CXCR2 inhibitor | CXCR2, CXCR1 | Phase 2 | Metastatic Castration-resistant Prostate Cancer; Melanoma Stage III; Myelodysplastic Syndromes; Metastatic Lung Non-Small Cell Carcinoma … | Jun 2027 |
| Icahn School of Medicine at Mount Sinai | reparixin Interleukin-8 receptor A modulator; Interleukin-8 receptor B modulator | CXCR1, CXCR2 | Phase 2 | Myelofibrosis (PMF) | Dec 2027 |
| NYU Langone Health | Ladarixin Interleukin-8 receptor A modulator; Interleukin-8 receptor B modulator | CXCR1, CXCR2 | Phase 1 | Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation | Aug 2027 |
Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation (1) Myelofibrosis (PMF) (1) Metastatic Castration-resistant Prostate Cancer (1) Melanoma Stage III (1) Myelodysplastic Syndromes (1) Metastatic Lung Non-Small Cell Carcinoma (1) Pancreatic Cancer (1) Advanced Lung Non-Small Cell Carcinoma (1) Pancreatic Ductal Adenocarcinoma (1) Recurrent Multiple Myeloma (1) Metastatic Colorectal Cancer (1) Metastatic Castrate-Resistant Prostate Cancer (mCRPC) (1)
small molecule (4)
NYU Langone Health (1) Icahn School of Medicine at Mount Sinai (1) Syntrix Biosystems (1) Memorial Sloan Kettering Cancer Center (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.